Seeking Alpha
We cover over 5K calls/quarter
Profile| Send Message|
( followers)  

Unilife Corporation (NASDAQ:UNIS)

F2Q 2014 Earnings Call

February 3, 2014 04:30 PM ET

Executives

Todd Fromer - KCSA Strategic Communications

Alan Shortall - Chairman and CEO

Ramin Mojdeh - President and COO

Analysts

Dennis Hulme - BBY

Jeremy Feffer - Cantor Fitzgerald

Keith Markey - Griffin Securities

Raj Denhoy - Jefferies & Company

Danielle Antalffy - Leerink

Jeffrey Cohen - Ladenburg Thalmann

Operator

Good day, ladies and gentlemen. Welcome to the Unilife Corporation Second Quarter Fiscal 2014 Earnings Conference Call. At this time, all participants are in a listen-only mode. Later, we will conduct a question and answer session and instructions will follow at that time. (Operator Instructions) As a reminder, this call is being recorded.

I would now like to introduce your host for today's conference, Todd Fromer, Managing Partner of KCSA Strategic Communication. Please go ahead, sir.

Todd Fromer

Thank you. Good afternoon, everyone, and good morning to all our Australian supporters. Thank you for joining us for the Unilife Corporation fiscal 2014 second quarter conference call.

Before we begin today, I would like to remind everyone that this conference call contains forward-looking statements. All statements that address operating performance, events or developments that we expect or anticipate to occur in the future are forward-looking statements. These forward-looking statements are based on management's beliefs and assumptions and not on information currently available to our management.

Our management believes that these forward-looking statements are reasonable as of when made. However, you should not place undue reliance on any such forward-looking statements because such statements speak only as of the date when made. We do not undertake any obligation to publicly update or revise any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

In addition, forward-looking statements are subject to certain risks and uncertainties that could cause actual results, events and developments to differ materially from our historical experience and our present expectations or projections. These risks and uncertainties include, but are not limited to, those described in Item 1A, Risk Factors, and elsewhere in our Annual Report on Form 10-K and those described from time-to-time in other reports, which we file with the Securities and Exchange Commission.

With nothing further, I would now like to turn the call over to Mr. Alan Shortall, Chairman and Chief Executive Officer of Unilife Corporation. Alan, the floor is yours.

Alan Shortall

Thank you, Todd. Good afternoon to those dialing in from the U.S.A. and a special good morning to those in Australia. First of all, I would like to introduce Ramin Mojdeh, Unilife's President and Chief Operating Officer, who is joining me on the call today.

Ramin Mojdeh

Good morning.

Alan Shortall

Thank you, Ramin. I am calling from Sydney, where I have been holding shareholder briefings and institutional investor meetings as part of a non-deal road show, and I stress, a non-deal road show. It has been great to catch up with so many of our Australian investors and I am very encouraged by their wonderful support. This has been a strong quarter for Unilife, in which momentum continues to build behind our product, our expertise and our capabilities.

We have signed several significant new contracts with the leading pharmaceutical companies, including Novartis, MedImmune and Hikma. As a result of our execution of these and other customer programs, revenue for this quarter is up more than 12%, compared to the first quarter of fiscal year 2014, and more than 400% compared to the same period last year. As I have said before, we continue to experience sequential quarter-to-quarter revenue growth in fiscal year 2014.

Cash payments from customers are also increasing. Since the start of the current fiscal year, we have invoiced more than $20 million. Most of that cash has been received since my last earnings call in November. This quarter has also seen us continue to narrow the loss per share. This has been done at the same time as we have been increasing our investments in R&D and expanding our operations.

Contract negotiations with the multitude of pharmaceutical companies are continuing across all of our product platforms. Many of these negotiations are at a very advanced stage. With so much business to begin [right at from signed] [ph] and prospective contracts, I am comfortable in our current cash position and I expect it will only continue to improve from here.

Given our favorable outlook for 2014 and beyond, I reiterate that we have no intension of doing any type of large secondary offering. It is also my intention to avoid using the ATM in the foreseeable future. Shall we wish to strengthen our cash position outside of receipts from customers I expect it will be via a debt financing program with a leading global healthcare investor. Should we elect to borrow [inaudible] program, it would be at favorable terms that I believe should be well received by the market.

First off, I would like to give you an update on recently signed contracts. I will start with those contracts that have been signed since our last earnings call.

Hikma. In November, we signed a long-term supply contract with Hikma, one of the largest and fastest growing generic injectable companies in the world. Hikma will be converting an initial list of 20 of their generic injectable products from vials into our Unifill prefilled syringes. We expect initial device sales will commence mid-year. It is my expectation that some of the devices we supply to Hikma this year will be used commercially.

Device sales to Hikma under the contract will increase to minimum unit volumes of 175 million units per year and I expect demand from Hikma for our products will end up exceeding those minimum unit volumes. The program with Hikma is moving forward at exceptional speed. We received the first milestone payment of $5 million in the second fiscal quarter of 2014 and may have already begun to receive additional milestone payments during the current quarter.

In total, we expect to receive $15 million in milestone payments during calendar year 2014, with an additional $20 million to follow. These total payments of $40 million are of course in addition to device sales.

Also, in November, we signed a significant agreement with MedImmune, the global biologic arm of AstraZeneca to customize and supply devices from our platform of wearable injectors for use with several target drug candidates. This is a significant customer supply relationship that I believe underlines our leadership position in the wearable injector market, which is expected to reach in excess of $8 billion in revenue by 2024. That's annual revenue.

I believe this MedImmune contract has strong potential to generate significant commercial revenue in the near future. We will continue to generate recurring revenue from MedImmune as we move forward in this program. In December 2013, we signed our first contract for our Ocu-ject platform with a global pharmaceutical company that is a market leader in ophthalmic therapies. They are seeking to use Ocu-ject to deliver a target injectable therapy into the eye.

Ocu-ject represents game-changing technology within the highly competitive and rapidly growing market of ocular injection therapies. The overall market is moving to prefilled syringes. Pharmaceutical companies are seeking to provide the best clinical outcomes with their competing drugs and there is no, I repeat, no competing technology to our knowledge that can deliver the small dose therapies with the accuracy and precision of Ocu-ject.

Revenue from this program will commence during the third quarter of fiscal 2014. I expect revenue from this program will continue as the program advances. Due to the competitive nature of this space for ocular therapies, it's not appropriate to give any more detail on the customer or their target drug at this time. However, as the program advances, I hope we can provide some color.

Based upon the game changing nature of the Ocu-ject platform and the number of other pharmaceutical companies who are seeking access to our technology, I expect additional contracts will be signed for Ocu-ject during 2014. Also, in December, we signed the second stage of our partnership with Novartis to supply clinical products from one our platforms of injectable drug delivery systems for use with a targeted early stage pipeline drug. Again, I can't say too much about this program at this stage for commercial and competitive reasons. However, I will say that our technology has helped to enable the delivery of this target drug through a new route of administration.

Without our device technology, it would have required surgery to deliver the drug into the target organ of the body. We have generated revenue under this Novartis program during the second quarter of fiscal year 2014, and additional revenue is expected going forward.

In regards to other previously signed contracts, I first like to give you an update on our program with Sanofi for the use of the Unifill Finesse with Lovenox. We are making excellent progress on this Sanofi program. I understand all parties are very pleased with the progress we made. I just want to say that we have a wonderful relationship with Sanofi and I expect that our partnership will continue to evolve moving forward.

In regards to milestone fees, we received the first payment of $5 million during the first quarter of fiscal year 2014. I am also very pleased to confirm that we have already received the second milestone payment of a further $5 million during the fiscal year third quarter. In addition, our EZMix supply contract with Biodel continues to proceed in a positive fashion. We expect to receive additional payments through the fiscal year as we support Biodel's schedule to commercialize their glucagon product in EZMix.

I would also like to remind quickly remind listeners that our supply contract with a customer for the use of our Unifill syringes with the generic version of an approved auto-immune therapy is continuing. Additional payments are expected for this program as the product heads towards approval and anticipated commercial launch.

Finally, I think it's important to say that there are some contracts that we have signed to-date that we have elected not to disclose. These are contracts that are not yet material and it's not appropriate to make any comment for commercial and competitive purposes. In most of these cases, I expect we will be able to say more as the program and the customer and the partnership moves to the next stage.

Our commercial pipeline continues to deepen and expand based on responses from a multitude of pharmaceutical companies, it's clear that demand continues to build for our game changing products, industry expertise and our customer-centric business model.

In regards to upcoming deal flow, there is a lot to look forward to for the remainder of fiscal year 2014 and beyond. Several contracts that I have anticipated, we will have had signed by December 2013, are still on track to be completed during the third and fourth quarters of fiscal year 2014. Some of these contracts are now at a late stage of negotiation.

There are also a number of additional contracts entering the late stage of our commercial pipeline. Some of these contracts will expand our relationship with the existing customers. Other contracts will be completed with new customers. These contracts will be for a planned of approved and late-stage biologics drugs and vaccines.

Indeed, for the largest market segments of injectable drugs, we are already well positioned within biologics, antithrombotics and generic injectables. We are also pleased with the progress that we are making to establish a position in the last remaining large market category. That category is vaccines. For a number of pharmaceutical companies recognize the competitive benefits of our Unifill platforms of prefilled syringes.

Financial update. Now let's take a look at our financials for the second quarter fiscal year 2014. As I said before, we are targeting sequential quarter-to-quarter growth in revenue and we also expect significant quarterly compares to the same period of the prior year. That's just what has been achieved by Unilife this quarter. Compared to the first quarter fiscal year 2014, we have increased revenue by more than 12%, and compared to the same period last year, we have increased revenue by 411%. As we continue to invest in R&D, we are also reducing our SG&A.

Our operating expense for the second quarter was $15.5 million, compared to $14.7 million for the same quarter in fiscal 2013. This reflected an increase in R&D investment and $1.6 million reduction in SG&A. Total net loss for the second quarter ended December 31, 2013, was $16.3 million, compared to the net loss of $14.6 million for the same quarter last year. Again, the increase in net loss is primarily attributable to an increase in R&D and interest expenses. We have significantly narrowed our adjusted net loss from $9.7 million in the same quarter last year down to $8.3 million. We have achieved this by continuing to increase our investment in R&D.

Adjusted net loss excludes share based compensation, depreciation and amortization and interest expense. As of December 31, 2013, we had $6.7 million in cash. This does not include $6.2 million in cash generated by the use of our ATM facility with Cantor Fitzgerald in January 2014.

As I said during my opening remarks, we are continuing to manage our cash position to minimize dilution to existing shareholders. I had periodic enquiries from analysts about why we choose to run our balance sheet as lean as we do during the period of rapid business expansion.

By this [non-traditional], we are very confident in our recurring cash revenue from customers. This cash revenue generation is highly predictable in nature. We believe that these customer cash receipts combined with a debt financing program will be sufficient to meet our business needs moving forward and while I have no intention of using the ATM facility again, it's still a good option to have available should there be a strategic benefit in its use.

There is much work going on internally to build production capacity to fulfill customer demand for a range of programs that are either already underway or about to commence. In terms of expanding our operations, this is an ongoing process that generates the steady increase in production capacities over time, so we are currently expanding our manufacturing capacity across a number of product platforms. We are also working with our suppliers to prepare them for rapid acceleration in unit volume requirements.

I can advise that we have commenced the installation of new clean rooms at our facility in York, Pennsylvania. These new clean rooms will be completed in a few months and ensure that all production space within the current footprint of our 165,000 square-foot facility is in full operation.

In summary, I'd quickly repeat what I consider to be my key takeaways for this call. Our revenue per quarter is increasing. Our cash position is expected to continue to strengthen. Our losses per quarter are narrowing while we are continuing to invest in our R&D and expand operations in response to customer demands and we have a rich commercial pipeline that is chaining with new customers and upcoming contracts. In short, I believe that the strong momentum we have generated in recent months is step to continue moving forward.

I would now like to open the call up to questions.

Question-and-Answer Session

Operator

Thank you. (Operator Instructions) Our first question comes from Dennis Hulme from BBY. Please go ahead.

Dennis Hulme - BBY

Good morning, Alan. Thanks for taking my question. I just had a question about the treatment of cash receipts. Firstly that your cash receipts for the half year were $12 million but you only reported revenue of $7 million. I see in some of the receipts are being treated as deferred revenue. Can you just talk about the policy going forward, the relationship between the receipts versus revenue?

Alan Shortall

Dennis, yes. Obviously we work on the GAAP (Inaudible) in the US and we worked with our accounts department and auditors in relation to deferred revenue. As you know I’ve been away for the last four, five weeks I haven't been involved in the detail and so I will actually pass that question over to Ramin, if I may. Ramin, would you handle that?

Ramin Mojdeh

Absolutely. Good morning. Yes. As you might imagine, the deferred revenue essentially is primarily in two areas and that has to do with the nature of the revenue, so it's either milestone recognized or it is amortized over a period of time, so that's naturally what you are going to see over time and you are going to see a pretty big build up of deferred revenue.

Dennis Hulme - BBY

Okay. Thank you. My second question is just about the deal -

Alan Shortall

Sorry. Go ahead, Dennis.

Dennis Hulme - BBY

Yes. Can you give any guidance about what to expect from the deal pipeline? You have a great half year just past, do you think you can match that in the next six months or will it take 12 months to match that? What's your sense from what you can see?

Alan Shortall

As I just said, Dennis, our pipeline is teeming. Much as I like to be able to stage these deals and transactions coming through in a nice neat manner of maybe once every two weeks or so it's not possible. We are often dealing with companies with 50,000, 80,000, 100,000 people in them, getting alignments to all the different departments and senior executives and getting signed off it takes some [inaudible] and the time is not always predictable. You look at the last quarter of the calendar year we have done three major transactions, Novartis, and also MedImmune and with Hikma. It's quite possible that we could have a quarter like that at any time going forward with this deal flow we have in our pipeline, but I just can't predict it, but I am very confident overall that 2014 is going to be a significant year for us in relation to the deals that we put on the table.

Dennis Hulme - BBY

Okay. Thanks very much. I look forward to seeing the deals come through.

Alan Shortall

Thank you.

Operator

Thank you. Our next question comes from Jeremy Feffer from Cantor Fitzgerald. Please go ahead.

Jeremy Feffer - Cantor Fitzgerald

Hi. I guess, Alan, good morning and good afternoon for the others. I guess, I want to start on revenues. I know you are not giving formal guidance and timing of a lot of these pipeline projects is still up in the air. Can you give us sort of a sense of what kinds of revenues, order of magnitude we might expect to see in the second half? Meaning, can we start to get approach a breakeven point or is the ramp still early enough that may get pushed out to next year?

Alan Shortall

Thanks. Look, again, and come back to reflecting on what we said and what we have actually demonstrated for this quarter sequential revenue growth over the last quarter. I think you will see that level of growth going forward. One of the competitive advantages we have as a company is that we are not focusing as an emerging companies building on revenues starting to grow. We are not focused on the next quarter or the next quarter, or this year or maybe mid-next year, or the end of next year, which is a bit of advantage we have is that we are actually building the opportunity that's on the table for us for the future. We have a [inaudible] positions where we are locking in long-term supply contracts 10, 15, 20 years, where we are actually locking off our competition in many ways. From that point of view R&D is [inaudible]. We continue to invest in that R&D and we continue to ram home the advantage that we have in many of these contracts and putting on the table, so our focus is not necessarily that shorter term. It's a longer term.

I think I have said this to you, Jeremy. It's very similar to the Amazon approach. It's not looking at that short-term, looking to building an [own a salable] [ph] position which we are now building so that we are taking full advantage of that opportunity we have over our competition, but if you look at the sequential growth that we are now delivering, I think going forward, you will see that as a trend.

Jeremy Feffer - Cantor Fitzgerald

Understood. Come back to the balance sheet quickly. Alan, you talked about pursuing this debt financing and you sort of held out for a little while, I think, as the pipeline has emerged I imagine your terms have started to swing more in your favor. What is going to be the final determining factor before you actually look to close a financing? I know you want to keep it lean, but just to provide yourself a backstop, do you want to announce some more deals or are you comfortable with how things look now just to be able to provide you with some additional cushion.

Alan Shortall

Yes. Exactly right. We had the option of putting a debt financing in place. Since I announced it pretty much, I think around May of last year. Again, as our company has strengthened and we have put some significant deals on the table our position in relation to negotiating terms for a long-term debt financing has got better, so we are locking in long-term debt. Obviously those terms are very important to us. We are now positioned where I think we can get very favorable terms to meet our expectations, but again as CEO, the best thing I can have is to have choices and we have choices. With our deals coming, with [funding tax] [ph] and from that perspective, I am very comfortable with cash position and we can pull the lever on the debt funding at any stage and I believe we will do so, well it's a question of implementing –the strategy which is not obviously publicly at the moment, but in terms of what we know is coming through with the deal flow we’ll pull that lever at the appropriate time.

Jeremy Feffer - Cantor Fitzgerald

Okay. Then last one for me. I'll jump back in queue. I recognize the sensitivity working with some of your partners. I know that confidentiality tends to stem from their end. At what point in terms of timing do you expect to be able to disclose more on the Ocu-ject deal? Does it depend on your ability to sign further Ocu-ject deals or was this entirely dependent on your partner?

Alan Shortall

It is both. We believe that Ocu-ject, because of its ability to accurately inject molecules and therapy into the eye will become the market standard, so from that perspective, we, as I said in my earnings call that we are pretty much dealing with everybody in that sector at the moment. Now, I believe we will become the standard, so we actually don't want to pre-empt that, so we are being very careful with those negotiations that were ongoing, but also we’re actually sensitive for our customer. I'll just give an example. I mean, two years ago, we announced the targeted organ delivery with a major global pharma. In November just gone by, we announced that that pharma was Novartis, at that stage Novartis were comfortable with us opening up that information, so it can be both.

Jeremy Feffer - Cantor Fitzgerald

On the Ocu-ject side, do you think at some point this year that partner and drug can be revealed?

Alan Shortall

I don't know that. That will depend talking with the customer, but as I also said early on in the call that I believe we will [inaudible] a number of those [units] [ph] for Ocu-ject this year. Now, some of those we may well be able to announce the name of the customer and give some more detail, but this is a significant opportunity for us going forward. I believe that this device will become the standard in terms of pharmaceutical companies being in compliance with the regulatory label.

Jeremy Feffer - Cantor Fitzgerald

Okay. That's helpful. Thank you.

Alan Shortall

Thank you.

Operator

Thank you. Our next question comes from the Keith Markey from Griffin Securities. Please go ahead.

Keith Markey - Griffin Securities

Hi, Alan and Ramin. Thank you for taking my question. I was just wondering could you first describe the reason for the sudden increase in interest expense and the second quarter without really concentrating increase in the debt outstanding.

Alan Shortall

Ramin, can I pass that one to you?

Ramin Mojdeh

If you don't mind, I need to look at that and get back to you, Keith.

Keith Markey - Griffin Securities

Okay. All right. Then I was wondering if you might be able tell us a little bit about the new contracts that were signed, but not yet disclosed that are immaterial at this point in time as you alluded to the possibility of having perhaps multi-tier relationships with the companies at this point. I was wondering if that was truly the case. Then also can you give us a sense as to the combined value of those contracts?

Alan Shortall

I can't give you the combined value. Some of these contracts are significant contracts that we are referring to, but we signed agreements that we haven't disclosed that are not material. It's part of the process and the agreements that we are able to sign are agreements that were able to sign similar in early stages with some of the agreements that we actually have announced now at the moment, so it's that part of that process. At this stage, we don't give the material and some of those agreements we have signed are not announced are actually which pharmas that we have already done deals with what we have announced and there were completely new pharmas on the way to the process. They are in the earlier stages which will lead to significant deals going forward. Some of them are at various ranges of size, but some of them are substantial.

Keith Markey - Griffin Securities

Okay. Then one last question. Can you give us a sense as to what proportion of you R&D expense for the quarter was related to existing contracts? In other words, fulfilling applications for those customers?

Alan Shortall

Ramin, can I hand that one to you?

Ramin Mojdeh

Keith, just a little over or about half of it. That's to do with the existing contracts. The rest of it has to do with all the new development of new platforms and for new customers.

Keith Markey - Griffin Securities

Great. Thanks very much.

Alan Shortall

Thanks.

Ramin Mojdeh

You're welcome.

Operator

Thank you. Our next question comes from Raj Denhoy from Jefferies & Company. Please go ahead.

Raj Denhoy - Jefferies & Company

Hi. Good afternoon, guys. I wonder if I could just press a little more on the cash issue. Without the cash flows came in so difficult to figure what's coming in what's going out in the quarter, your cash position went down modestly. You generated a bit more on the top line, expenses stayed roughly the same, so I am curious as we think about this quarter and then the quarters four, how do we sort of model the cash position in essence, because there are so many moving parts you are not giving us all the piece which kind of put it together. I guess, just broadly speaking, can you give us any sense on what the operational cash flow is going to be for you over the next couple of quarters?

Alan Shortall

Yes. We'll look as I said early in the earnings call, in the first six months of the year, we invoiced approximately $20 million. The cash position went slightly down in the second quarter, but I also said in my call, we received the second payment of $5 million in this current quarter. Also, further payments from Hikma.

We expect that those pace of payments going forward will increase, so that you would see an increase of flow cash coming in that that is different from what is deferred revenue recognized or [ROIs] to cash, so that you will see that level of cash coming out as you go forward with these programs, and particularly with the wearable injector programs as they leveled up and the customization fees come in inception.

Raj Denhoy - Jefferies & Company

Right. I guess, the genesis of the question is that your cash position remains relatively tight as you mentioned. Then if you think about the deals you have announced, they are going to require additional capacity perhaps. Then you also continue to spend pretty aggressively. We are just trying to comfortable with that all those things balance out in a sense that you are not being forced to do something you wouldn't want to do in terms of having to raise cash, because my sense is that store remains potential risk here and I am just curious how would you respond to that.

Alan Shortall

Obviously, there's things going on in the background in terms of deal flow and cash that I can't talk about obviously, but again, I would reiterate and they are never are confident I want to say we will not begin secondary offering in any way. I have actually said during my call that I think at this stage it's still likely that we will even chip into the ATM as a - because of the level of cash that we have coming in from some of these programs which we have a high of confidence on and also with the debt funding that we have available to us, which we have been pretty much pull the trigger on if needed.

Raj Denhoy - Jefferies & Company

Okay. Again, don't know if you have had a chance that kind of the pervious question about interest expense was up significantly in the quarter. I mean, did you do anything that would - I am not aware. Are you doing any sort of debt financing? Have you done something recently?

Alan Shortall

No. Not to my knowledge. It may well will actually relate to a settlement with (Inaudible), but I am not actually sure, Raj, I have been traveling on the roads for last four weeks, so I haven't been involved in the specific detail and my apologies for that, but we will get back to you on it.

Raj Denhoy - Jefferies & Company

Okay. Thank you.

Alan Shortall

Okay. Thank you.

Operator

Thank you. Our next question comes from Danielle Antalffy from Leerink. Please go ahead.

Danielle Antalffy - Leerink

Thanks so much. Good afternoon, everyone. A quick question on the manufacturing. Again, to me this is now sort of an execution story from the manufacturing perspective. I was hoping, Alan, if you could give us a little bit of color on where your current manufacturing capacity is and how quickly it's going to ramp as we move through the year based on the existing contracts you have already signed here today.

Alan Shortall

Okay. Again, there contracts were put in place for multiple products right across the whole range and I believe that pretty much every product in our platforms will be in full [play] with contracts within the next few months. Our business is broken down where have got four general managers that are fully responsible for delivery of those products and develop and quality regulatory manufacturing, so we can do these planning, implement them and do it rapidly.

One of the benefits we have in the regulatory process of the pharmaceutical companies using our devices as primary factory retailers. We get usually a better 12 to 18-month through the year window to which we know we need to start providing a high volume product, so the planning on that limitation, we have already done it and executed personnel fee, so that the high volume math will go forward without technical challenge is one just replication. Our teams knows all our plans for cleaning out the whole of our manufacturing facility and some of that caught up with us for deals that we know are coming, but yes we haven't made public.

That plan is in place. We are already engaged with high volume equipment suppliers and we actually will have that equipment in place, in time tuned ready-to-go with SAP fully operational and to comment on that product we have aligned in time to provide programs for any of our Pharmaceutical customers in any of those programs. That plan is already in place and being executed well.

Danielle Antalffy - Leerink

Okay. Great. Then I was wondering if you could give a little color. You have historically in the past given some color around the cash burn rate you expect going forward. I know you talked about it at a higher level, but I was wondering if you frame some numbers for us, so we can appropriately model that.

Alan Shortall

Look, I don't think there's going to be much in the historic we have delivered over the last two years or so. I mean, if you look at our numbers this quarter, we are very conscious in running a very mean and lean operation. I mean, we have significantly reduced our SG&A at about $1.6 million. We will continue to look at running mean and lean, but we will also continue where we feel that's prudent to continue to invest in R&D. As I said, we are building an [favorable] position in the marketplace. We know the market leaders and injectables hub delivery systems in differentiated drug delivery systems. We are going to continue to run on that by investing in R&D, and we believe that that's building significant value going forward for our shareholders.

I can't give you the specific, but bear in mind also, we don't wake up in the morning and say I have got a great idea for new product. We are developing products to specific unmet needs in the market to which we actually know that deserve demand for those products when we come up with the solution. As we have currently done with the products that we have done the agreements for and as I said every one of our products is going to be in play within the next few months.

Danielle Antalffy - Leerink

Got it. Okay. Thanks. One last question. Apologies if I missed those in the prepared remarks and I think you did cover here, but historically you have given some color about the contract negotiations pipeline. I think you there were 35 advanced negotiations. Of course you signed some of those, so just wondering if you could frame the deal pipeline for us a little bit.

Alan Shortall

Well, again, I don't want to get into the specifics except to say I think we demonstrated like in the last quarter where we had three major significant deals. As I said during my call, that we are a [prioritized] chaining with new commercial contracts on the road show. I would like to be able to stay nicely once every four - doesn't work that way unfortunately, but I do believe overall in the short, medium and longer term, in particular 2014, is going to be a monumental year for us in relation to the context of news delivered on the table.

Danielle Antalffy - Leerink

Okay. Thanks so much.

Alan Shortall

Thank you.

Operator

Thank you. Our next question comes from the Jeffrey Cohen from Ladenburg Thalmann. Please go ahead.

Jeffrey Cohen - Ladenburg Thalmann

Hi. Thanks for taking my questions. Perhaps you could elaborate a little bit as far as the ATM facility, what are your views and what is left?

Alan Shortall

Jeff, I think we view is possibly about 16 or 17. That's the guesstimate of my part. I don't know the specific numbers, but it's approximate and I think we probably have about $20 million or so $32 million left. Again, that's really just insurance policy to have as we go forward, as we manage their cash position.

I have stated clearly in the call today, I actually think at this stage, it is likely that we would actually be using this. Going forward from now, I think we are in a good position in terms of our cash that we are expecting to come in, but I also would like to point out that we have reduced that ATM facility. In the last two or three times it was specifically only been approached half of its with institutional investors that want to take a prime position in our stock and a number of those cases where we have done it, they have actually increased the position substantially going forward, so we have had strategic benefit, issued minimal stock, maintained our cash position as I say again gives us again the comfort to be able to get these deals in place, so that we are actually in a strong position as I said mostly likely that we won't need to use it again going forward.

Jeffrey Cohen - Ladenburg Thalmann

Okay. Great. Thank you. The next question is, if you could please add me to the list. I am curious as far as the $4.4 million interest expense for the quarter, which is a bit unusual. I would love to get some clarity on there.

Alan Shortall

Okay. We will cover that.

Jeffrey Cohen - Ladenburg Thalmann

Lastly, I know you have been already, but is it possible that you give us some kind of review from kind of $30,000 for example and as far as the pipeline looking forward. Have you found that any negotiations whether they would be earlier mid-stage, have actually seized or stopped at any of that has been added just generally speaking. Have some been loss and some been added? With the net effect being adds or losses?

Alan Shortall

Jeff, I have to say, to my knowledge, again, (Inaudible), but I am constantly in touch with our team and especially our commercial team and with Ramin. I have to say that I am not aware of any deal that was in the pipeline starting within let's say having answered the first 20% of any communication in a deal flow and that will be using a three-year process. I am not aware of having lost any. I am aware though of a constant increase through the back of that line going forward pretty much on a week-to-week basis.

I believe that we are now being recognized as the leading company in this whole area and the pharmaceutical customers, the feedback we are getting is and that realize the value that we bring to the table where we are cost competitive with what they are currently using. We don't need to change our infrastructure on our cost, which seamlessly finish lines.

We don't introduce any new material in to the fluid path, so there is no raising risk warrant and we are price competitive and they get all the advantages in the marketplace where they can use the differentiation of our products and the benefits to the end user and leverage that to take market share from the competitors and increase the revenues. That's the driver for our business now. The pharmaceutical companies, they now realize that and that's why our commercial pipeline continues to expand constantly.

Jeffrey Cohen - Ladenburg Thalmann

Thank you. One more if I may. What's the timeline on the Hikma contract to get to that minimum of 175 million units on an annual basis? Is that - two years or four years?

Alan Shortall

I would expect to say and we haven't released that information. To the extent I don't think we are fully aware, because Hikma are looking at their global rollout, but I do know that they are moving rapidly with that program and their intention is to get full benefits of the differentiation with our product is quickly as they possibly can, so I think they would reach that number closer to the two-year mark rather than the four-year mark.

Jeffrey Cohen - Ladenburg Thalmann

Got it. Thanks very much for taking the questions.

Alan Shortall

Thank you, Jeff.

Operator

Thank you and I am not showing any further questions. I would now like to turn the call back to Alan Shortall for any closing remark.

Alan Shortall

Well, thank you everybody. I really appreciate you turning up today and I look forward to the next quarter. As I said, we are in a very good, strong position and we will continue to build on that strength and entrench our position as the leader in injectable drug delivery systems globally. Thank you for attending the call today.

Operator

Ladies and gentlemen, thank you for participating in today's conference. This does conclude today's program. You may all disconnect. Everyone, have a great day.

Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.

THE INFORMATION CONTAINED HERE IS A TEXTUAL REPRESENTATION OF THE APPLICABLE COMPANY'S CONFERENCE CALL, CONFERENCE PRESENTATION OR OTHER AUDIO PRESENTATION, AND WHILE EFFORTS ARE MADE TO PROVIDE AN ACCURATE TRANSCRIPTION, THERE MAY BE MATERIAL ERRORS, OMISSIONS, OR INACCURACIES IN THE REPORTING OF THE SUBSTANCE OF THE AUDIO PRESENTATIONS. IN NO WAY DOES SEEKING ALPHA ASSUME ANY RESPONSIBILITY FOR ANY INVESTMENT OR OTHER DECISIONS MADE BASED UPON THE INFORMATION PROVIDED ON THIS WEB SITE OR IN ANY TRANSCRIPT. USERS ARE ADVISED TO REVIEW THE APPLICABLE COMPANY'S AUDIO PRESENTATION ITSELF AND THE APPLICABLE COMPANY'S SEC FILINGS BEFORE MAKING ANY INVESTMENT OR OTHER DECISIONS.

If you have any additional questions about our online transcripts, please contact us at: transcripts@seekingalpha.com. Thank you!

Source: Unilife's CEO Discusses F2Q 2014 Results - Earnings Call Transcript
This Transcript
All Transcripts